Literature DB >> 8864824

Induction of diabetes in NOD<-->C57BL/6 embryo aggregation chimeras by cyclophosphamide through preferential depletion of C57BL/6 lymphocytes.

F Colucci1, K Lejon, C M Cilio, I Bergqvist, T Matsunaga, D Holmberg.   

Abstract

The majority of embryo aggregation (EA) mouse chimeras between non-obese diabetic (NOD) mice and C57BL/6 (B6) mice show clear signs of insulitis frequently accompanied by beta-cell destruction. Less than 5% of these chimeras, however, spontaneously progress to autoimmune diabetes, an incidence far lower than observed in NOD mice. The resistance in chimeras can be accounted for by the target organ chimerism and/or the immune system chimerism. To investigate the mechanism(s) controlling diabetes resistance in these mice, we studied a total of 92 NOD<-->B6 EA chimeras that showed overt lymphoid chimerism and treated 34 chimeras with cyclophosphamide (CY), a compound known to precipitate an acute form of insulin-dependent diabetes mellitus (IDDM) in pre-diabetic NOD mice, by interfering with regulatory mechanisms. We found that CY-treated EA chimeras displayed an increase in the NOD:B6 lymphocyte ratio and 32% of them developed diabetes that could be adoptively transferred to irradiated NOD or NOD-rag-2-/- mice. These findings suggest that lymphocyte chimerism rather than beta-cell chimerism accounts for diabetes resistance in NOD<-->B6 EA chimeras and that the susceptibility to CY-induced diabetes may be related to the proportion of NOD versus B6 lymphoid cells.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8864824     DOI: 10.1006/jaut.1996.0066

Source DB:  PubMed          Journal:  J Autoimmun        ISSN: 0896-8411            Impact factor:   7.094


  1 in total

1.  "A Japanese gentleman of the Samurai tradition": Takeshi Matsunaga 1945-2003.

Authors:  Francesco Colucci; Elizabeth Simpson; Anne McLaren; Satoshi Hayakawa; Elisabet Andersson; Lucia Mincheva-Nilsson; Vladimir Baranov
Journal:  Immunogenetics       Date:  2003-10-14       Impact factor: 2.846

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.